Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Eisenberger

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Clinical Advances in Hematology & Oncology : H&O|May 10, 2018
Research in drug development for advanced prostate cancerMario Eisenberger
The Oncologist|December 22, 2005
Achieving treatment goals for hormone-refractory prostate cancer with chemotherapyWilliam Berry, Mario Eisenberger
The New England Journal of Medicine|July 13, 2004
Progress toward identifying aggressive prostate cancerMario Eisenberger, Alan Partin
Current Opinion in Supportive and Palliative Care|July 9, 2010
Is there a role for chemotherapy in nonmetastatic prostate cancer?Daniel Keizman, Mario Eisenberger
JAMA Oncology|August 26, 2016
Intermittent Androgen Deprivation: Primum Non Nocere-"First Do NO Harm"Maha Hussain, Mario Eisenberger
European Urology|April 23, 2014
Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward?Daniel Suzman, Mario Eisenberger
Oncology (Williston Park, N.Y.)|December 18, 2015
Chemotherapy in Prostate Cancer Beyond Metastatic CRPCJong Chul Park, Mario Eisenberger
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2005
Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?"Charles J Ryan, Mario Eisenberger
Nature Clinical Practice. Urology|May 13, 2006
Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture?Andrew J Armstrong, Mario Eisenberger
The New England Journal of Medicine|October 31, 2017
Abiraterone in Metastatic Prostate CancerJohann de Bono, Mario Eisenberger, Oliver Sartor
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Clinical Advances in Hematology & Oncology : H&O|May 10, 2018
Research in drug development for advanced prostate cancerMario Eisenberger
The Oncologist|December 22, 2005
Achieving treatment goals for hormone-refractory prostate cancer with chemotherapyWilliam Berry, Mario Eisenberger
The New England Journal of Medicine|July 13, 2004
Progress toward identifying aggressive prostate cancerMario Eisenberger, Alan Partin
Current Opinion in Supportive and Palliative Care|July 9, 2010
Is there a role for chemotherapy in nonmetastatic prostate cancer?Daniel Keizman, Mario Eisenberger
JAMA Oncology|August 26, 2016
Intermittent Androgen Deprivation: Primum Non Nocere-"First Do NO Harm"Maha Hussain, Mario Eisenberger
European Urology|April 23, 2014
Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward?Daniel Suzman, Mario Eisenberger
Oncology (Williston Park, N.Y.)|December 18, 2015
Chemotherapy in Prostate Cancer Beyond Metastatic CRPCJong Chul Park, Mario Eisenberger
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2005
Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?"Charles J Ryan, Mario Eisenberger
Nature Clinical Practice. Urology|May 13, 2006
Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture?Andrew J Armstrong, Mario Eisenberger
The New England Journal of Medicine|October 31, 2017
Abiraterone in Metastatic Prostate CancerJohann de Bono, Mario Eisenberger, Oliver Sartor
Pageof 7